Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Collegium Pharmaceutical (COLL) has provided an update.
Collegium Pharmaceutical, Inc. finalized its acquisition of Ironshore Therapeutics Inc. on September 3, 2024, with a merger deal valued at approximately $525 million in cash and an additional potential milestone payment of $25 million. To fund this acquisition, Collegium secured a $325 million loan from BioPharma Credit PLC and associated lenders. The completion of the deal was publicly announced via a press release and detailed in a corporate presentation on the company’s website.
Find detailed analytics on COLL stock on TipRanks’ Stock Analysis page.